New pages

Jump to navigation Jump to search
New pages
Hide registered users | Hide bots | Hide redirects
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)
  • 10:11, 16 May 2024 ‎Avacincaptad pegol (hist | edit) ‎[3,387 bytes] ‎Muhammad Waleed (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV...")
  • 07:06, 16 May 2024 ‎Diclofenac Patch (hist | edit) ‎[48,613 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr...")
  • 06:42, 16 May 2024 ‎Cortisone Acetate (hist | edit) ‎[14,098 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen...")
  • 06:32, 16 May 2024 ‎Clocortolone Pivalate (hist | edit) ‎[4,446 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed...")
  • 06:20, 16 May 2024 ‎Scorpion (hist | edit) ‎[12,448 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u...")
  • 10:58, 15 May 2024 ‎Lodoxamide (hist | edit) ‎[6,537 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...")
  • 23:48, 13 May 2024 ‎Fezolinetant (hist | edit) ‎[5,682 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}")
  • 20:38, 13 May 2024 ‎Talquetamab-tgvs (hist | edit) ‎[5,078 bytes] ‎Muhammad Waleed (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent...")
  • 14:50, 13 May 2024 ‎Nirsevimab-alip (hist | edit) ‎[5,780 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection...")
  • 05:30, 12 May 2024 ‎Somatrogon-ghla (hist | edit) ‎[12,743 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.con] |genericName=somatrogon-ghla |aOrAn=a |drugClass=human growth hormone analog |indicationType=treatment |indication=pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone |hasBlackBoxWarning=Yes |adverseReactions=injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, v...")
  • 20:21, 11 May 2024 ‎Elfabrio (hist | edit) ‎[3,351 bytes] ‎Rithish Nimmagadda (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio...")
  • 19:36, 11 May 2024 ‎Exxua (hist | edit) ‎[44 bytes] ‎Rithish Nimmagadda (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}")
  • 13:10, 9 May 2024 ‎Epcoritamab-bysp (hist | edit) ‎[11,459 bytes] ‎Rithish Nimmagadda (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=VSRN }}")
  • 10:37, 9 May 2024 ‎FUTIBATINIB (hist | edit) ‎[1,225 bytes] ‎Hafiza Amna Qadeer (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER, MD |OTC=Yes |genericName=FUTIBATINIB |aOrAn=a |drugClass=Kinase Inhibitor |indicationType=treatment |indication=* of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. |adverseReactions=1* Nail Toxicity, stomatitis, dry skin, dry eye, alopecia 2* Musculos...")
  • 04:57, 9 May 2024 ‎Sotagliflozin (hist | edit) ‎[5,290 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}")
  • 21:32, 8 May 2024 ‎EXXUA (hist | edit) ‎[11,572 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Gepirone |aOrAn=a |drugClass=extended-release tablets |indicationType=treatment |indication=major depressive disorder (MDD) in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, nausea, insomnia, abdominal pain, and dyspepsia |blackBoxWarningTitle=WARNING: SUICIDAL THOUGHTS AND BEHAVIORS |blackBoxWarningBody=SEE FULL PRESCRIBING INFORMATION FOR...")
  • 14:10, 8 May 2024 ‎FRUZAQLA (hist | edit) ‎[9,129 bytes] ‎Rithish Nimmagadda (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma...")
  • 13:32, 8 May 2024 ‎Fruzaqla (hist | edit) ‎[49 bytes] ‎Rithish Nimmagadda (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}")
  • 17:27, 7 May 2024 ‎Zuranolone (hist | edit) ‎[7,608 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...")
  • 22:57, 3 May 2024 ‎Xacduro- sulbactam and durlobactam (hist | edit) ‎[11,950 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin...")
  • 18:20, 3 May 2024 ‎Perfluorhexyloctane (hist | edit) ‎[2,821 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}")
  • 15:29, 2 May 2024 ‎Trofinetide (hist | edit) ‎[4,393 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}")
  • 03:29, 2 May 2024 ‎Zavegepant (hist | edit) ‎[4,397 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic...")
  • 21:51, 1 May 2024 ‎Omaveloxolone (hist | edit) ‎[5,828 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=omaveloxolone }}")
  • 15:46, 1 May 2024 ‎Nirsevimab (hist | edit) ‎[15,269 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=Nirsevimab |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season |hasBlackBo...")
  • 18:57, 30 April 2024 ‎Isosulfan Blue (hist | edit) ‎[5,962 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...")
  • 18:46, 30 April 2024 ‎Ibuprofen Lysine (hist | edit) ‎[15,666 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...")
  • 18:27, 30 April 2024 ‎Prussian blue (hist | edit) ‎[14,070 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...")
  • 18:14, 30 April 2024 ‎Botulism Antitoxin (hist | edit) ‎[18,011 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...")
  • 15:23, 29 April 2024 ‎Trastuzumab emtansine (hist | edit) ‎[40,575 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...")
  • 15:23, 25 April 2024 ‎Daprodustat (hist | edit) ‎[7,973 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...")
  • 21:14, 24 April 2024 ‎Tranexamic (hist | edit) ‎[23,023 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...")
  • 21:06, 24 April 2024 ‎Bexagliflozin (hist | edit) ‎[5,887 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}")
  • 03:47, 21 April 2024 ‎BRENZAVVY- bexagliflozin (hist | edit) ‎[12,281 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re...")
  • 16:30, 19 April 2024 ‎Sparsentan (hist | edit) ‎[8,644 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...")
  • 19:33, 17 April 2024 ‎SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY (hist | edit) ‎[2,387 bytes] ‎Hafiza Amna Qadeer (talk | contribs) (Created blank page)
  • 08:08, 17 April 2024 ‎Elranatamab-bcmm (hist | edit) ‎[32,900 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:08, 17 April 2024 ‎Palovarotene (hist | edit) ‎[39,234 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:08, 17 April 2024 ‎Pozelimab-bbfg (hist | edit) ‎[2,443 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:07, 17 April 2024 ‎Motixafortide (hist | edit) ‎[26,106 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:07, 17 April 2024 ‎Momelotinib (hist | edit) ‎[34,123 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:06, 17 April 2024 ‎Cipaglucosidase alfa-atga (hist | edit) ‎[38,322 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:05, 17 April 2024 ‎Etrasimod (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:05, 17 April 2024 ‎Zilucoplan (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 ‎Bimekizumab (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 ‎Vamorolone (hist | edit) ‎[11,981 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 ‎Mirikizumab-mrkz (hist | edit) ‎[5,301 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:03, 17 April 2024 ‎Toripalimab-tpzi (hist | edit) ‎[46,018 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:02, 17 April 2024 ‎Fruquintinib (hist | edit) ‎[25,648 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
  • 07:52, 17 April 2024 ‎Taurolidine, heparin (hist | edit) ‎[9,993 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)
Retrieved from "https://www.wikidoc.org/index.php/Special:NewPages"